How much funding has Asia Mattelab raised?

Asia Mattelab has raised $9.4M in total funding. Key investors include Temasek Holdings, EDBI, Tessa Therapeutics, Plug and Play Ventures.

Who is the CEO of Asia Mattelab?

Brice Oh is the CEO of Asia Mattelab. The company was founded in 2013.

Where is Asia Mattelab located?

Asia Mattelab is headquartered in Singapore, Singapore.

What funding stage is Asia Mattelab at?

Asia Mattelab is currently at the Active stage.

How many employees does Asia Mattelab have?

Asia Mattelab has approximately 1-10 employees.

Asia Mattelab

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

ServiceSingapore, SingaporeFounded 2013· One of 1986 Service companies tracked by AMPulse

Distributes 3D bioprinters and scientific lab equipment for research and industrial laboratories, providing consultation and technical support.

CEO / Founder: Brice Oh
Team Size: 1-10
Stage: Active
Total Funding: $9.4M
Latest Round: Series A
Key Investors: Temasek Holdings, EDBI, Tessa Therapeutics, Plug and Play Ventures

Technology & Products

Key Products

3D bioprinters (e.g., r3bEL bioprinter) and scientific lab equipment for bioscience research and education.

Technological Advantage

Partnership with SE3D for r3bEL bioprinter distribution provides access to bioprinting technology without in-house R&D; focus on customer consultation and after-sales service builds trust in research community.

Differentiation

Value Proposition

Provides access to specialized 3D bioprinting technology (e.g., r3bEL bioprinter) and lab equipment with expert consultation, reducing procurement complexity and ensuring proper implementation for bioscience research and education.

How They Differentiate

As a distributor rather than manufacturer, focuses on customer consultation and support in Southeast Asia, unlike direct bioprinter makers like CELLINK or Allevi.

Market & Competition

Target Customers

Research laboratories, universities, pharmaceutical companies, biotechnology firms

Industry Verticals

Pharmaceuticals; Biotechnology; Medical Research; Education

Competitors

CELLINK, Allevi

Growth & Milestones

Growth Metrics

Reported annual revenue of $2.0 million in 2024

Major Milestones

Incorporated in 2013; Established distribution partnerships with multiple scientific equipment manufacturers; Listed in VoxelMatters directory as an AM industry participant

Notable Customers

A*STAR; Tessa Therapeutics; Pfizer Asia-Pacific; NUS Medicine

https://mattelabasia.com

Why this company matters

MatteLab operates as a specialized distributor of 3D bioprinters and scientific lab equipment, targeting research laboratories, universities, pharmaceutical companies, and biotechnology firms in Southeast Asia. Founded in 2013 and based in Singapore, the company positions itself as a local intermediary for global equipment manufacturers seeking entry into the region's growing bioscience market.

The company's core offering includes the r3bEL bioprinter, distributed through a partnership with SE3D, alongside equipment from partners such as H.E.L Group, Nanomagnetics Instruments, InProcess-LSP, and Lightgo. MatteLab provides technical consultation and after-sales support, differentiating itself from direct bioprinter manufacturers like CELLINK and Allevi by focusing on service and localized expertise rather than in-house R&D.

MatteLab serves customers including A*STAR, Tessa Therapeutics, Pfizer Asia-Pacific, and NUS Medicine. The company has raised S$12.7 million from investors including Temasek Holdings, EDBI, Tessa Therapeutics, and Plug and Play Ventures, and reported annual revenue of $2.0 million in 2024. Its market position depends on maintaining strong manufacturer partnerships and the ability to support complex bioprinting workflows in a region where such expertise remains scarce.